Lance Alstodt, CEO of BioRestorative Therapies, discusses the development of its lead cell therapy candidate BRTX-100, the evolving regulatory and manufacturing landscape for autologous therapies, and how regenerative platforms could reshape treatment paradigms for chronic conditions.
Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.
Shaukat Ali, PhD, and Jim Huang, PhD, provide a better understanding about some of the advantages of prefilled syringes, methods for manufacturing, and the syringe types commercially available.
Salvatore Forte, MS, believes adherence to the dosing regimen, as well as compliance to the injection protocol, are essential for treatment success in both these use-cases. Hence, the request for a connected, smart PFS is growing just as much to tackle poor medication adherence and compliance issues.
Contributor Cindy H. Dubin highlights innovations from key players in parenteral delivery and prefilled syringes, with focuses on safety, meeting regulatory requirements, cost, fill/finish, and dosing.
Lalit Saxena explains how technology transfer in biologics manufacturing is an inherently complex process that requires the simultaneous control of multiple scientific, technical, and operational variables.
COMPANY PROFILE
Kenox Pharmaceuticals is a specialty contract development, manufacturing, and testing organization advancing nasal, inhalation, and ophthalmic drug products. We provide end-to-end support from early-stage research and formulation development through GMP fill-finish and analytical testing, enabling successful Phase I and II clinical trials. Our expertise includes both non-sterile and sterile drug–device combination products, ensuring quality and reliability across diverse development programs. Kenox is distinguished by deep technical knowledge, broad industry experience, and flexibility in managing complex device technologies, from conventional inhalers to advanced platforms such as Soft Mist inhalers. Click here for more.
Why Early Development Requires a Different Decision Model
Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …
The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.
Key messages:
Start
…
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
April 22 – Particle Design Technology
April 29 – Controlled Release